Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

6 of the best annual results on the ASX in FY25 and 6 of the worst!

Each reporting season, we like to recap some of the best annual results on the ASX and some of the worst as well. Amidst all the companies, it is easy for investors to get lost amidst the mire of information. And so we like to single out particular companies that impressed and others that did…

ByNick SundichAugust 26, 2025

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors, a time many reconsider if their thesis still holds, many choose to buy into a stock or sell, some will receive dividends (either expectedly or unexpectedly) whilst others will be disappointed. While you may not…

ByNick SundichJuly 23, 2025

Is it possible for an investor to ‘time the market’ or is it just a myth?

Is it possible at all to time the market? Some will tell you it is possible, but they were probably just lucky and/or were not even trying to. Others will tell you it is not possible, but they are most likely trying to find an excuse to blame poor short-term performance. Let's take a serious look…

ByNick SundichJuly 21, 2025

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the ASX generally, or perhaps the investment strategy of buying these worst performing shares at the start of a new year (either a calendar or financial year), thinking they will rebound.Many will be considering this strategy,…

ByNick SundichJuly 14, 2025

Percheron Therapeutics (ASX:PER) picks itself up in 2025

Percheron Therapeutics (ASX:PER) It's a fact of life in the biotech game: drugs often fail in clinical development. Percheron Therapeutics (ASX:PER) had one of those failures late last year. It was working on Avicursen for the treatment of Duchenne Muscular Dystrophy and had reason to believe from earlier work that the drug had potential to…

ByStuart RobertsJuly 7, 2025

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

It is a New Financial Year, so it's time to outline 11 Top ASX Stocks to Buy in FY26. Why 11 you might ask? Because 11 is the number of 'GICS' (Global Industry Classification Sectors) on the ASX, and we're picking one from each sector. Our 11 Top ASX Stocks to Buy in FY26! Energy: Ampol…

ByNick SundichJuly 7, 2025

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Israel’s strikes on Iran, and the subsequent responses, led to the typical "risk off" moves professional investors usually make when faced with uncertainty. But what exactly does "risk off" mean and how relevant is it for retail investors? Should you be risk off too or should you ride out geopolitical uncertainty?Few would've predicted Israel would've…

ByNick SundichJune 18, 2025

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left the ASX in the past 2 years than any 2 year period since the 1990s recession - whether being brought out by private equity or a big industry player, delisting to a penny stock exchange…

ByNick SundichJune 6, 2025

Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so

Will Ozempic hurt healthcare stocks? Investors who've been selling healthcare stocks left right and centre - except Novo Nordisk of course, now the largest stock in Europe by market capitalisation - believe it will. But even though we hear these arguments loud and clear, we think these fears are overblown.Ozempic is a weight-loss drug that…

ByNick SundichMay 28, 2025

ESG Investing in 2025: How can I tell if a stock or fund is ethical or ESG compliant?

ESG investing is becoming increasingly popular with investors. But as this happens, it begs the question as to just how you can tell if an applicable stock or fund is ESG friendly? So how can I tell if my stock or fund is ESG compliant? As tough as it is to disappoint our readers, there is no…

ByNick SundichMay 26, 2025